dihexa raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-11-27 and is reviewed periodically as new material appears.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
| Property | Value | Notes |
|---|---|---|
| Chemical name | N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Common full name in research literature. |
| Class | Synthetic peptide | Modified angiotensin IV analog. |
| Related compound | Angiotensin IV | Parent peptide fragment. |
| Proposed target | HGF/c-Met pathway | Described as an HGF mimetic; not fully confirmed. |
| Development status | Preclinical research | No widely approved clinical use. |
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
=== Agents of the Four Seasons and Guards === Hinagiku Kayo (花葉 雛菊, Kayō Hinagiku) Voiced by: Yuka Nukui (Japanese); Celeste Perez (English) The Agent of Spring, possesses the ability of "Life Acceleration". She was kidnapped and held captive by the "Insurgents", natural enemies of the Agents of the Four Seasons, for almost ten years, during which spring did not occur. She has had feelings for Rosei since she was little. As an illegitimate daughter born of the head of Kayo family and his mistress, the previous Agent of Spring Kobai Yukiyanagi, her family treats her poorly even after her return. In her captivity Hinagiku was abused by the leader Misuzu Henderson both physically, emotionally and mentally. Hinagiku was also forced to cultivate plants for the Insurgents to be used as illegal drugs. After eight years Hinagiku snapped and nearly kills Misuzu and escaped, but she isolated herself from her duties for two years as the abuse affected her deeply. Sakura Himedaka (姫鷹 さくら, Himedaka Sakura) Voiced by: Kana Hanazawa (PV), Yoshino Aoyama (anime) (Japanese); Marisa Duran (English) The Agent of Spring's Guard. She is an attendant who never stopped looking for Hinagiku, suffering regret for not being able to protect her charge. The love she felt for Itecho surpassed the adoration of a student towards her master, but due to a certain event she hates him deeply. Even after the Town of Spring and Winter stopped searching for Hinagiku, she continued to search for her alone.
Half-Life: C.A.G.E.D. (also stylized as Half-Life: Caged) is a game modification of Half-Life by Cayle George and Future Games Select released on September 21, 2017. Made using the GoldSrc engine, the mod includes a single-player campaign in which the player must escape from a closely guarded prison. The mod was released on Microsoft Windows via Steam and was made available on macOS and Linux in December 2017.
=== Headache Disorders === Both isoforms of PACAP (PACAP-38 and PACAP-27) have been implicated in migraine pathogenesis. A Danish research group led by Dr. Messoud Ashina found that intravenous infusion of PACAP-38 induced migraine attacks in 58% of people with migraine, whilst the corresponding migraine induction rate was 55% for PACAP-27. Treatments with monoclonal antibodies have been investigated to target PACAP or its receptors for the treatment of primary headache disorders. In a phase 2, proof of concept study published in 2024, a monoclonal antibody treatment targeting PACAP (denoted Lu AG09222) reduced the number of migraine days in patients suffering from treatment-resistant migraines. Attempts to target its receptors have been less successful. Amgen's AMG-301, which targets the PAC1 receptor, failed to show greater efficacy than placebo in phase II trials.
Sources: en.wikipedia.org
Benzhydrocodone (INN; contracted from benzoate-hydrocodone) is an opioid prodrug of the morphinan class. Its chemical structure consists of hydrocodone coupled with benzoic acid. Benzhydrocodone itself is inactive and acts as a prodrug to hydrocodone upon cleavage of the benzoate portion of the molecule. It is designed to be an opioid analgesic with a low chance of recreational use. Created by Kempharm, Inc., a biopharmaceutical company in Coralville, Iowa, President and CEO, Travis Mickle, believes the molecular-based approach to abuse deterrent may be more effective than many formulation-based approaches. When approved, Apadaz received a labeling that highlighted all relevant aspects of the drug, including the lower abuse profile compared to traditional hydrocodone-acetaminophen. The labeling showed several items supporting a lower abuse profile than traditional hydrocodone-acetaminophen; namely, a lower Drug Liking in the first two hours after intranasal abuse (snorting), and the conversion of benzhydrocodone to hydrocodone in vitro being a "difficult process" — with benzhydrocodone being a more difficult drug to abuse according to FDA advisory committee documents.
Duke Nukem Forever had been a project with a troubled development history at 3D Realms, who had created the Duke Nukem series, since sometime prior to 2000. Due to financial difficulties in 2009, 3D Realms was forced to downsize and ultimately lay off most of the development staff. Take-Two Interactive sued 3D Realms for failing to deliver Duke Nukem Forever. Pitchford, who had prior industry relations with many 3D Realms staff including George Broussard, learned that many of the 3D Realms team were still eager to develop Duke Nukem Forever, working out of their homes on what they could. Pitchford negotiated with Take-Two to bring many of the former 3D Realms staff into a new studio called Triptych Games, housed at Gearbox's headquarters, to continue working on Duke Nukem Forever following 3D Realms' closure in 2009. As a result, 3D Realms sold the rights to Duke Nukem and the existing work on Duke Nukem Forever to Gearbox around February 2010. Take-Two and Gearbox subsequently announced in September 2010 that Gearbox would finish production of Duke Nukem Forever. Duke Nukem Forever was released in June 2011, and received negative critical reception on release, with most of the criticism directed towards the unfinished, rushed state of the game. Despite the criticism, the game topped the charts on release and made a profit. 3D Realms had initially sued Gearbox in June 2013 for unpaid royalties over Duke Nukem Forever, but dropped the suit by September 2013, with 3D Realms' founder Scott Miller stating that it was a misunderstanding on its part.
5α-Reductase inhibitors are inhibitors of the enzyme 5α-reductase, and are a type of specific androgen synthesis inhibitor. 5α-Reductase is an enzyme that is responsible for the conversion of testosterone into the more potent androgen dihydrotestosterone (DHT). There are three different isoforms of 5α-reductase, types 1, 2, and 3, and these three isoforms show different patterns of expression in the body. Relative to testosterone, DHT is about 2.5- to 10-fold more potent as an agonist of the androgen receptor. As such, 5α-reductase serves to considerably potentiate the effects of testosterone. However, 5α-reductase is expressed only in specific tissues, such as skin, hair follicles, and the prostate gland, and for this reason, conversion of testosterone into DHT happens only in certain parts of the body. Furthermore, circulating levels of total and free DHT in men are very low at about one-tenth and one-twentieth those of testosterone, respectively, and DHT is efficiently inactivated into weak androgens in various tissues such as muscle, fat, and liver. As such, it is thought that DHT plays little role as a systemic androgen hormone and serves more as a means of locally potentiating the androgenic effects of testosterone in a tissue-specific manner. Conversion of testosterone into DHT by 5α-reductase plays an important role in male reproductive system development and maintenance (specifically of the penis, scrotum, prostate gland, and seminal vesicles), male-pattern facial/body hair growth, and scalp hair loss, but has little role in other aspects of masculinization.
=== House prices === The median house price in Bromley Town ward was £327,000 in 2014, compared to £295,444 in Plaistow and Sundridge, and £480,000 in Bickley. 37% of houses in Bickley were detached, more than other wards. In all wards, over 60% of houses were owned by households, peaking at 88.2% in Hayes and Coney Hall. In 2020, the average cost of a house was £519,619.
Sources: en.wikipedia.org
=== Mechanism of catalysis === The catalytic site of caspase-3 involves the thiol group of Cys-163 and the imidazole ring of His-121. His-121 stabilizes the carbonyl group of the key aspartate residue, while Cys-163 attacks to ultimately cleave the peptide bond. Cys-163 and Gly-238 also function to stabilize the tetrahedral transition state of the substrate-enzyme complex through hydrogen bonding. In vitro, caspase-3 has been found to prefer the peptide sequence DEVDG (Asp-Glu-Val-Asp-Gly) with cleavage occurring on the carboxy side of the second aspartic acid residue (between D and G). Caspase-3 is active over a broad pH range that is slightly higher (more basic) than many of the other executioner caspases. This broad range indicates that caspase-3 will be fully active under normal and apoptotic cell conditions.
=== Lifestyle interventions === Individuals with all stages of the CKM syndrome have reduced chances of entering or progressing to stages 1 to 4 using lifestyle interventions. These interventions include eating a healthy diet, health-promoting physical activity (e.g., doing at leaset 150 minutes/week of aerobic exercise plus 2-3 strength trainings), and dietary-based weight loose including bariatric surgery if dietary methods do not reduce bodily weight.
=== Medical === Typical applications for pentobarbital include use as a sedative, a short-term hypnotic, or a preanesthetic as well as for treatment of insomnia and control of convulsions in emergencies. Abbott Pharmaceutical discontinued manufacture of their Nembutal brand of pentobarbital capsules in 1999, largely replaced by the benzodiazepine family of drugs. Pentobarbital can reduce intracranial pressure in Reye syndrome, treat traumatic brain injury and induce coma in cerebral ischemia patients. Pentobarbital-induced coma has been advocated in patients with acute liver failure that is refractory to mannitol. Pentobarbital is also used as a veterinary anesthetic agent and euthanasia drug.
He is also one of only two players in history to have two 40-30 seasons (Barry Bonds being the other). Bagwell is also the only first baseman to reach both 400 home runs and 200 stolen bases. He is just one of 21 players in history to win both a Rookie of the Year Award and an MVP. His 1,529 RBI during the span of his playing career ranked second for all hitters (first among right-handed hitters), and he was fifth in home runs. He was in the top 10 in the MVP voting five times. From 1994 to 2003, he led all first basemen in stolen bases, doubles, hits, runs, walks, and extra-base hits, was second in games and RBI, and was third in home runs. He is the Astros' all-time leader in home runs and RBI and is the first Astro to win an MVP. In addition to stealing over 200 bases in his career, Bagwell contributed significantly around the field as a whole. During one series against Pittsburgh in 1994, the Pirates shifted while he batted, and Bagwell responded with seven opposite-field hits. A standout defender at first base, he won the 1994 Gold Glove award. Remarked The Sporting News, "he's an extraordinary fielder who excels at charging bunts and throwing runners out at second and third. Although he has average speed, he's one of the game's smartest baserunners. ..." From 1999 to 2000, his 295 runs scored led the major leagues and set a National League two-season record.
=== Linear trap and FTICR === Linear traps can be used to improve the performance of FT-ICR (or FTMS) systems. As with 3D ion traps, the duty cycle can be increased to nearly 100% if ions are accumulated in a linear trap, while the FTMS performs other functions. Unwanted ions that can cause space charge problems in the FTMS can be ejected in the linear trap to improve the resolution, sensitivity, and dynamic range of the system, although the system parameters used to optimize such signal characteristics co-vary with one another.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.
No, dihexa is a synthetic compound derived from the structure of angiotensin IV. Angiotensin IV occurs naturally, but dihexa has modifications that change its properties. It is not a standard dietary component.
The main hypothesis is that dihexa interacts with the hepatocyte growth factor system, possibly through c-Met signaling. This interaction may influence synaptogenesis and neuronal plasticity. The exact molecular target remains an active area of study.
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.